Carta Healthcare buys trial data abstraction counterpart Realyze Intelligence
AI-powered clinical data abstraction firm Carta Healthcare has acquired cancer trial-focused counterpart Realyze Intelligence.
The takeover will add Realyze’s “clinician-trained” artificial intelligence (AI) system to Carta’s clinical data identification and capture platform. Financial details were not disclosed.
In a press statement, Carta CEO Brent Dover said, “From clinical trials to clinical registries, clinicians face insurmountable amounts of data ripe with valuable information to improve care practices and patient outcomes.
“We are inspired by Realyze Intelligence’s shared ability to use clinician-trained AI and a human-in-the-loop approach to maximize insights from clinical data, for clinical trials and cancer registries.”
Realyze claims its clinician-trained AI tech can assemble appropriate patient cohorts in seconds. The firm cites several US cancer centers, including the Memorial Sloan Kettering Cancer Center Innovation Hub, as users.
Merger
San Francisco-based Carta was founded in 2019 as a provider of abstraction services to health systems across the US, including both community hospitals and academic medical centers. It lists Mass General Brigham, CommonSpirit, and Grady as current customers.
Realyze was established in 2020 as a portfolio company of UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC.
In May, the firm’s technology was lauded in a clinical study focused on breast cancer. According to the researchers, “the study demonstrates the utility of Realyze’s validated AI software in unlocking real-world data and empowering healthcare researchers to improve patient health outcome.”
Realyze CEO and founder Aaron Brauser welcomed the takeover, predicting it would form an effective patient-trial matching operation, explaining, “High-quality, timely data is essential for accurately identifying eligible patients, yet much of it remains trapped in EHRs and other systems.
“We are excited to revolutionize clinical trial matching and reuse the data to enhance research, optimize care pathways and improve patient outcomes with Carta Healthcare.”
DepositPhotos/thaneeh.gmail.com